Abstract:Metformin's potential in treating ischemic stroke and neurodegenerative conditions is of growing interest. Yet, the absence of established systemic and brain pharmacokinetic (PK) parameters at relevant pre-clinical doses presents a significant knowledge gap. This study highlights these PK parameters and the importance of using pharmacologically relevant pre-clinical doses to study pharmacodynamics (PD) in stroke and related neurodegenerative diseases. An LC-MS/MS method to measure metformin levels in plasma, brain, and cerebrospinal fluid (CSF) was developed and validated. In vitro assays examined brain tissue binding and metabolic stability. Intravenous (IV) bolus administration of metformin to C57BL6 mice covered low to high dose range maintaining pharmacological relevance. Quantification of metformin in the brain was used to assess brain pharmacokinetic parameters, such as unidirectional blood-to-brain constant (Kin) and unbound brain-to-plasma ratio (Kp, uu, brain). Metformin exhibited no binding in the mouse plasma and brain and remained metabolically stable. It rapidly entered the brain, reaching detectable levels in as little as 5 minutes. A Kin value of 1.87 {plus minus} 0.27 µl/g/min was obtained. As the dose increased, Kp, uu, brain showed decreased value, implying saturation, but this did not affect an increase in absolute brain concentrations. Metformin was quantifiable in the CSF at 30 minutes but decreased over time, with concentrations lower than those in the brain across all doses. Our findings emphasize the importance of metformin dose selection based on pharmacokinetic parameters for pre-clinical pharmacological studies. We anticipate further investigations focusing on pharmacokinetics and pharmacodynamics (PKPD) in disease conditions, such as stroke. Significance Statement The study establishes crucial pharmacokinetic parameters of metformin for treating ischemic stroke and neurodegenerative diseases, addressing a significant knowledge gap. It further emphasizes the importance of selecting pharmacologically relevant pre-clinical doses. The findings highlight metformin's rapid brain entry, minimal binding, and metabolic stability. The necessity of considering pharmacokinetic parameters in pre-clinical studies provides a foundation for future investigations into metformin's efficacy for neurodegenerative disease (s).

Repurposing metformin to treat age-related neurodegenerative disorders and ischemic stroke

Metformin Improves Cognition of Aged Mice by Promoting Cerebral Angiogenesis and Neurogenesis

Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?

Repurposing metformin: A potential off‐label indication for ischaemic stroke?

Metformin acts directly in the brain to slow features of neurodegeneration

Exploring the Pharmacological Potential of Metformin for Neurodegenerative Diseases

Repurposing and clinical attributes of antidiabetic drugs for the treatment of neurodegenerative disorders

Repurposing metformin: an old drug with new tricks in its binding pockets

Metformin as a potential therapeutic for neurological disease: mobilizing AMPK to repair the nervous system

Novel targets and therapies of metformin in dementia: old drug, new insights

Therapeutic Effects of Metformin on Central Nervous System Diseases: A Focus on Protection of Neurovascular Unit

Reconsidering repurposing: long-term metformin treatment impairs cognition in Alzheimer's model mice

Beneficial effects of metformin treatment on memory impairment

Emerging role of Metformin in Alzheimer's disease: A translational view

Repurposing Metformin for the Treatment of Atrial Fibrillation: Current Insights

Pharmacological Approaches Using Diabetic Drugs Repurposed for Alzheimer's Disease

Administration of metformin rescues age-related vulnerability to ischemic insults through mitochondrial energy metabolism

To Use or Not to Use Metformin in Cerebral Ischemia: A Review of the Application of Metformin in Stroke Rodents

Repurposing of Anti-Diabetic Agents As a New Opportunity to Alleviate Cognitive Impairment in Neurodegenerative and Neuropsychiatric Disorders

Evaluation of Systemic and Brain Pharmacokinetic Parameters for Repurposing Metformin Using Intravenous Bolus Administration

Exploring the dual character of metformin in Alzheimer's disease